Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report
The long-term treatment regimen with RC48 is feasible for metastatic UTUC after RNU, and RC48 monotherapy is suitable as first-line therapy for selected patients.
Authors
- Wei Jiang (ORCID: https://orcid.org/0000-0001-6534-8612)
- Suoshi Jing (ORCID: https://orcid.org/0000-0002-7194-5293)
- Bo Zhao (ORCID: https://orcid.org/0000-0002-8612-5597)
- Bin Zhang (ORCID: https://orcid.org/0000-0002-5876-1238)
- Weiping Li (ORCID: https://orcid.org/0000-0002-5534-5925)
Institutions
- People's Liberation Army 401 Hospital (CN)
- Zhejiang Entry-Exit Inspection and Quarantine Bureau (CN)
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.3389/fonc.2024.1419882
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Gansu Province